BriaCell Therapeutics (CVE:BCT) Trading Down 3.8% – Should You Sell?

Shares of BriaCell Therapeutics Corp. (CVE:BCT) were down 3.8% during mid-day trading on Thursday . The company traded as low as C$10.60 and last traded at C$10.60. Approximately 3,402 shares changed hands during trading, a decline of 73% from the average daily volume of 12,671 shares. The stock had previously closed at C$11.02.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright decreased their price target on shares of BriaCell Therapeutics from C$18.00 to C$15.00 in a research note on Thursday, September 19th.

BriaCell Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 129.63 and a quick ratio of 128.68. The stock’s 50 day simple moving average is C$10.60 and its two-hundred day simple moving average is C$10.60. The stock has a market cap of C$168.68 million and a price-to-earnings ratio of -28.19.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.